Scientists have discovered a possible weakness in glioblastoma, a highly aggressive and deadly form of brain cancer. Researchers at The Ohio State University Comprehensive Cancer Center found that blocking a protein called SET stopped tumor formation in preclinical models. Their approach focused on restoring the activity of an enzyme called PP2A, which glioblastoma cells seem to suppress. The team also observed that disrupting related proteins made the cancer cells more vulnerable to radiation therapy. The study, published in the May 2026 issue of Cancer Letters, was supported by funding from the National Institutes of Health, the National Cancer Institute, and the university's cancer center. The findings suggest that reactivating PP2A could help glioblastoma cells respond better to treatment, potentially improving the effectiveness of radiation and chemotherapy for patients with this type of brain cancer. Researchers are now examining whether targeting SET or other proteins that inhibit PP2A can be done safely and whether it enhances standard glioblastoma treatments. They also looked into an FDA-approved antipsychotic drug that increases PP2A activity, but it is not yet suitable for treating glioblastoma and should not be used for this purpose outside of clinical trials. These results are still preliminary and have not been tested in human patients. The research team is now working on ways to evaluate whether this strategy can improve the effectiveness of existing therapies for glioblastoma.